Literature DB >> 16000885

Impaired coronary collateral vessel development in patients with metabolic syndrome.

Hasan Turhan1, Ayse S Yasar, Ali R Erbay, Ertan Yetkin, Hatice Sasmaz, Irfan Sabah.   

Abstract

BACKGROUND: The development of coronary collateral vessels is the physiological response of myocardial tissue to hypoxia or ischemia, which results in an increase in blood supply to the tissue. However, a lack of collateral vessels or the presence of poor collateralization in some patients despite the presence of significant coronary stenosis or obstruction and evidence of myocardial ischemia suggest that some other factors may affect the development of collateral circulation. In the present study we aimed to evaluate coronary collateral circulation in patients with metabolic syndrome with advanced coronary artery disease and compare the results with those of patients without metabolic syndrome.
METHOD: The study population comprised 102 patients with metabolic syndrome and advanced coronary artery disease (>or=90% diameter stenosis in at least one major epicardial coronary artery) and 102 control participants without metabolic syndrome who also had >or=90% diameter stenosis in at least one major epicardial coronary artery. The diagnosis of metabolic syndrome was based on the National Cholesterol Education Program Adult Treatment Panel III clinical definition. Coronary collateral vessels were analysed according to the Cohen and Rentrop grading system. Both groups were also divided into two additional groups according to the Rentrop collateral score as patients with poor collateral circulation (Rentrop score 0-1) and good collateral circulation (Rentrop score 2-3).
RESULTS: The mean Rentrop collateral score for patients with metabolic syndrome was significantly lower than for those without metabolic syndrome (1.38+/-0.79 compared with 1.99+/-1.08, respectively, P<0.001). When two groups were compared with respect to poor and good collateral circulation, poor collateral circulation was found to be significantly higher in the metabolic syndrome group (70% compared with 32%, respectively, P<0.001). Moreover, multivariate logistic regression analysis revealed a significant relationship between poor collateral circulation and metabolic syndrome (odds ratio=4.29, 95% confidence interval=1.73-10.69, P=0.002).
CONCLUSION: We have shown for the first time that the development of coronary collateral vessels is poorer in patients with metabolic syndrome with advanced ischemic heart disease than in control participants without metabolic syndrome. Thus, it can be suggested that metabolic syndrome is one of the significant factors affecting the development of coronary collateral vessels adversely.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16000885     DOI: 10.1097/00019501-200508000-00004

Source DB:  PubMed          Journal:  Coron Artery Dis        ISSN: 0954-6928            Impact factor:   1.439


  14 in total

Review 1.  Redox-dependent mechanisms in coronary collateral growth: the "redox window" hypothesis.

Authors:  June Yun; Petra Rocic; Yuh Fen Pung; Souad Belmadani; Ana Catarina Ribeiro Carrao; Vahagn Ohanyan; William M Chilian
Journal:  Antioxid Redox Signal       Date:  2009-08       Impact factor: 8.401

2.  Impaired coronary collateral growth in the metabolic syndrome is in part mediated by matrix metalloproteinase 12-dependent production of endostatin and angiostatin.

Authors:  Tracy Dodd; Luke Wiggins; Rebecca Hutcheson; Erika Smith; Alla Musiyenko; Brenda Hysell; James C Russell; Petra Rocic
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-04-18       Impact factor: 8.311

3.  NAD(P)H oxidase-derived peroxide mediates elevated basal and impaired flow-induced NO production in SHR mesenteric arteries in vivo.

Authors:  Xiaosun Zhou; H Glenn Bohlen; Steven J Miller; Joseph L Unthank
Journal:  Am J Physiol Heart Circ Physiol       Date:  2008-07-03       Impact factor: 4.733

4.  MicroRNA-145 restores contractile vascular smooth muscle phenotype and coronary collateral growth in the metabolic syndrome.

Authors:  Rebecca Hutcheson; Russell Terry; Jennifer Chaplin; Erika Smith; Alla Musiyenko; James C Russell; Thomas Lincoln; Petra Rocic
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-02-07       Impact factor: 8.311

Review 5.  Exercise training and peripheral arterial disease.

Authors:  Tara L Haas; Pamela G Lloyd; Hsiao-Tung Yang; Ronald L Terjung
Journal:  Compr Physiol       Date:  2012-10       Impact factor: 9.090

6.  Neuron-derived neurotrophic factor functions as a novel modulator that enhances endothelial cell function and revascularization processes.

Authors:  Koji Ohashi; Takashi Enomoto; Yusuke Joki; Rei Shibata; Yasuhiro Ogura; Yoshiyuki Kataoka; Yuuki Shimizu; Takahiro Kambara; Yusuke Uemura; Daisuke Yuasa; Kazuhiro Matsuo; Satoko Hayakawa; Mizuho Hiramatsu-Ito; Toyoaki Murohara; Noriyuki Ouchi
Journal:  J Biol Chem       Date:  2014-04-06       Impact factor: 5.157

7.  Metabolic syndrome and its components reduce coronary collateralization in chronic total occlusion: An observational study.

Authors:  Tong Liu; Zheng Wu; Jinghua Liu; Yun Lv; Wenzheng Li
Journal:  Cardiovasc Diabetol       Date:  2021-05-10       Impact factor: 9.951

8.  A device for performing automated balloon catheter inflation ischemia studies.

Authors:  Silas J Leavesley; Whitley Ledkins; Petra Rocic
Journal:  PLoS One       Date:  2014-04-25       Impact factor: 3.240

9.  Time-related alteration in flow- (shear stress-) mediated remodeling in resistance arteries from spontaneously hypertensive rats.

Authors:  Odile Dumont; Gilles Kauffenstein; Anne-Laure Guihot; Nathalie C Guérineau; Pierre Abraham; Laurent Loufrani; Daniel Henrion
Journal:  Int J Hypertens       Date:  2014-05-08       Impact factor: 2.420

10.  Influence of high-density lipoprotein cholesterol on coronary collateral formation in a population with significant coronary artery disease.

Authors:  Po-Chao Hsu; Ho-Ming Su; Suh-Hang Juo; Hsueh-Wei Yen; Wen-Chol Voon; Wen-Ter Lai; Sheng-Hsiung Sheu; Tsung-Hsien Lin
Journal:  BMC Res Notes       Date:  2013-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.